HERC1 Regulates Breast Cancer Cells Migration and Invasion

Fabiana Alejandra Rossi ¹, Ezequiel Hernán Calvo Roitberg ¹, Juliana Haydé Enrique Steinberg ¹, Molishree Umesh Joshi ², Joaquín Maximiliano Espinosa ²,³,⁴ and Mario Rossi ¹,*

1 Instituto de Medicina Translacional (IIMT), CONICET-Universidad Austral, Pilar, B1629AHJ Buenos Aires, Argentina; frossi-conicet@austral.edu.ar (F.A.R.); ecalvo-conicet@austral.edu.ar (E.H.C.R.); jenrique-conicet@austral.edu.ar (J.H.E.S.)
2 Functional Genomics Facility, University of Colorado School of Medicine, Aurora, CO 80045, USA; molishree.joshi@cuanschutz.edu (M.U.J.); joaquin.espinosa@cuanschutz.edu (J.M.E.)
3 Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA
4 Linda Crnic Institute for Down Syndrome, University of Colorado School of Medicine, Aurora, CO 80045, USA
* Correspondence: mrossi-conicet@austral.edu.ar; Tel.: +54-02304387423

Simple Summary: Breast cancer has the highest incidence and mortality in women worldwide, and, despite formidable advances in its prevention, detection, and treatment, the development of metastasis foci still represents a significant reduction in patients’ survival and life quality. The Ubiquitin-Proteasome System plays a fundamental role in the maintenance of protein balance, and its dysregulation has been associated with malignant transformation and tumor cells invasive potential. The objective of our work was focused on the identification of ubiquitination-related genes that could represent putative molecular targets for the treatment of breast cancer dissemination. For that purpose, we performed a genetic study and identified and validated HERC1 (HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase Family Member 1) as a regulator of migration and invasion. We confirmed that its depletion reduces tumorigenicity and the appearance of metastasis foci and determined that HERC1 protein expression inversely correlates with breast cancer patients’ overall survival. Altogether, we demonstrate that HERC1 might represent a novel therapeutic target in breast cancer.

Abstract: Tumor cell migration and invasion into adjacent tissues is one of the hallmarks of cancer and the first step towards secondary tumors formation, which represents the leading cause of cancer-related deaths. This process is considered an unmet clinical need in the treatment of this disease, particularly in breast cancers characterized by high aggressiveness and metastatic potential. To identify and characterize genes with novel functions as regulators of tumor cell migration and invasion, we performed a genetic loss-of-function screen using a shRNA library directed against the Ubiquitin Proteasome System (UPS) in a highly invasive breast cancer derived cell line. Among the candidates, we validated HERC1 as a gene regulating cell migration and invasion. Furthermore, using animal models, our results indicate that HERC1 silencing affects primary tumor growth and lung colonization. Finally, we conducted an in silico analysis using publicly available protein expression data and observed an inverse correlation between HERC1 expression levels and breast cancer patients’ overall survival. Altogether, our findings demonstrate that HERC1 might represent a novel therapeutic target for the development or improvement of breast cancer treatment.

Keywords: HERC1; invasion; breast; cancer; target

1. Introduction

The development of metastasis represents the principal cause of death in patients with solid tumors [1]. The invasive potential of malignant cells is characterized by a series of molecular and genetic modifications that increase their invasive potential, allowing them to
penetrate the extracellular matrix and spread in the surrounding tissues [2]. These changes are associated with alterations in a wide variety of posttranslational modification patterns, including ubiquitylation [3]. The Ubiquitin Proteasome System (UPS) plays a fundamental role in almost every single cellular process, and therefore it is not surprising that genetic alterations, abnormal expression, or dysfunction of different components of this cascade are often associated with malignant transformation of tumor cells and the development of metastatic processes [4–10].

To find novel therapeutic targets for the treatment of cancer, we focused our attention on the identification of genes related to the UPS that had novel functions as positive regulators of migration, using a triple negative breast cancer (TNBC)-derived cell line. This subtype of breast cancer (BC) is characterized by high metastatic rates, hormonal independence, and lack of targeted therapies [11–13].

We performed a shRNA genetic screen targeting different UPS genes, using a combination of Boyden chambers and in vivo experiments as functional assays. After the selection procedure, we identified HERC1 as a candidate positive regulator of tumor cell migration and invasion. HERC1 is a ubiquitin ligase, and our in vitro and in vivo experiments demonstrated that its depletion decreases invasiveness in highly aggressive breast cancer cells. Moreover, an in silico analysis of HERC1 protein levels in breast cancer patients’ samples indicated that high expression in primary tumors correlates with decreased survival, compared to low-expressing tumors. These results highlight the potential of HERC1 as a novel putative therapeutic candidate for cancer treatment.

2. Materials and Methods

2.1. Cell Lines and Cell Culture

The human breast cancer MDA-MB-231, MDA-MB-436, and embryonic kidney Hek293T cell lines were obtained from the ATCC and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) (Natocor, Córdoba, Argentina), 50 U/mL penicillin–streptomycin (Gibco), and 200 µM L-glutamine (Gibco) at 37 °C and 5% CO2 in a humidified incubator. ATCC uses morphology, karyotyping, and PCR-based approaches to confirm the identity of human cell lines. Mycoplasm contamination was evaluated monthly by PCR, and cell lines were cultured less than three months.

2.2. shRNA Screening

A pool of plasmids encoding 1883 shRNAs targeting 407 different components related to the ubiquitylation pathway inserted in the pLKO.1 backbone produced by The RNAi Consortium (TRC, Sigma-Aldrich, St. Louis, MO, USA; Table S1) was obtained from the University of Colorado Cancer Center Functional Genomics Shared Resource. One milligram of the shRNA library plasmid DNA at 100 ng/mL was mixed with 4 mg of packaging plasmid mix (pD8.9 and pCMV-VSVG lentiviral packaging plasmids at a 1:1 ratio) and incubated with 30 mg of Polyethylenimine (Polysciences, Warrington, MO, USA) for 15 min at RT. The entire mixture was then added to a 100 mm dish containing Hek293T packaging cells at 75% confluence. Six hours after transfection, media on cells was replaced with complete DMEM, and, 48 h after media replacement, the supernatant from each dish of packaging cells (now containing lentiviral library particles) was filtered through 0.45 mm cellulose acetate filters and stored at −80 °C until use. Target cells were seeded at $8 \times 10^5$ cells/well in 6-well plates and then transduced with the lentivirus. After 48 h, the infective media was removed, and target cells were selected for 5 days with a 0.5 µg/mL puromycin (Sigma-Aldrich, St. Louis, MO, USA) DMEM medium. Cells were propagated for 14 days before use.

The following shRNAs were used for the generation of stable cell lines containing individual shRNAs targeting HERC1: TRC number 7243, sequence: 5′ GCCACATTAGT-TACTCTAAA 3′ (shRNA #1); TRC number 7244, sequence: 5′ GCTGATAAAGTCGTCCT-CAA 3′ (shRNA #2).
2.3. shRNA Library Preparation and Sequencing

The library preparation strategy uses genomic DNA and two rounds of PCR to isolate the shRNA cassette and prepare a single strand of the hairpin for sequencing by means of an XhoI restriction digest in the stem loop region. After purity analysis of the sequencing library, barcode adaptors were linked to each sample to allow a multiplexing strategy. A HiSEQ 2500 HT Mode V4 Chemistry Illumina instrument (Illumina, San Diego, CA, USA) was used for that purpose and each sample was quantified and mixed together at a final concentration of 10 ng/mL. Samples were sequenced with a simple 1 × 50 run, and on average 1.2 × 10^6 reads were obtained per sample (>600 × shRNA library complexity).

2.4. shRNA Screen Sequencing Data Analysis

shRNA screen sequencing data were analyzed in a similar fashion to RNA-seq data. Briefly, quality control was performed with FastQC, and reads were trimmed to include only shRNA sequences using FASTQ trimmer and filtered with the FASTQ Quality Filter. Reads were then aligned to a custom reference library of shRNA sequences using Bowtie2.

2.5. Boyden Chamber Migration Assay

Cells were starved for 24 h (DMEM 0.1% FBS). After trypsinization, 5 × 10^4 were added to the top chamber of 24-well Boyden chambers (8 µm pore size membrane; BD Bioscience, Bedford, MA, USA), and medium was added to the bottom chambers and incubated for 24 h (DMEM 10% FBS). Non-migratory cells were removed, and, following membrane fixation, cells were stained with 4′,6-diamidino-2-phenylindole (Invitrogen, Waltham, MA, USA) and mounted. The membrane was then fully imaged using an Axio Observer Z1 Inverted Epi-fluorescence microscope (Carl Zeiss Microscopy GmbH, Munich, Germany) with montage function. Image analysis was performed with Fiji software [14], using an automated analysis macro to measure the number of nuclei per Boyden chamber.

For the migration screen, 6.6 × 10^5 starved MDA-MB-231 cells expressing the shRNA library (or control cell line) were plated onto 6-well Boyden chambers (8 µm pore size membrane; BD Bioscience, Bedford, MA, USA) in assay medium. After 24 h of incubation, the non-migratory cells were collected from the upper chamber, propagated, and allowed to re-migrate eleven times for enrichment purposes. The non-migratory cells of 8 Boyden chambers were combined per each selection cycle (to ensure a >700 library coverage) and the percentage of non-migratory cells in each case was determined in 24-well plates as described before.

2.6. Quantitative PCR

Total RNA was extracted from cell lines using TRIZol reagent (Invitrogen) according to the manufacturer’s instructions and complementary cDNA synthesis was carried out using M-MLV reverse transcriptase in the presence of RNasin RNase inhibitor (Promega, Madison, NJ, USA) and an oligo(dT) primer (Invitrogen).

Total DNA was extracted from cell lines, primary cultures or fixed tissues using DNeasy Blood and Tissue kit (Qiagen, Germantown, MD, USA).

Quantitative real time PCR amplification, using specific primer sets at a final concentration of 300 nM, was carried out using the FastStart Essential DNA Green Master kit (Roche, Mannheim, Germany) at an annealing temperature of 60 °C for 35 cycles and a CFX96 PCR Detection System (Biorad, Hercules, CA, USA). PCR primers were all intron spanning for mRNA expression analysis; expression was calculated for each gene by the comparative CT (ΔCT) method with GAPDH for normalization. Primer sequences are as follows: HERC1: 5′ AGGTTAAGCTGTTGGAGAAG 3′ (Fw), 5′ GCCATGAGAGGTATAAG 3′ (Rv) and GAPDH: 5′ TGCCACCAACACTGCTTAC 3′ (Fw), 5′ GGCATGACTGTGTTAGAG 3′ (Rv) for cDNA measurement. Human GAPDH: 5′ TACTACCGGTCTTTACGGCG 3′ (Fw), 5′ TCGAACAGGAGGAAGAAGGAGGGA 3′ (Rv) and mouse GAPDH: 5′ CCTGGCGATGGCTCGACTT 3′ (Fw), 5′ ATGCCACCCAGCCCCAGGAA 3′ (Rv) for DNA measurement.
2.7. Area-Based Analysis of Proliferation Rate

This experiment was based on an area-based imaging assay reported previously [15]. Briefly, $1 \times 10^3$ cells were seeded in 96-well plates and incubated overnight to allow cell attachment. Images were then acquired under bright field illumination every 6 h for 3 days using a 10× air objective and Zen Blue 2011 software (Zeiss) for image acquisition. Image analysis was performed with Fiji software, using an automated analysis macro to measure the occupied area by cells.

2.8. 3D Clonogenic Assay

In total, $1 \times 10^3$ cells were plated on 100 mm dishes and medium was replaced every 3 days for 15 days. At this point, dishes were washed with 1× PBS and methanol-fixed for 15 min. Dishes were then re-washed and stained with a 0.05% crystal violet solution for 1 h. Exceeding staining solution was then removed by immersion into a tap water containing recipient, after which dishes were air-dried, photographed, and analyzed with the OpenCFU software [16].

2.9. Wound Healing Assay

In total, $2.5 \times 10^5$ cells were seeded in 24-well culture plates per well. Confluent monolayers were starved during 24 h in 0.1% FBS-supplemented DMEM medium and a single scratch wound was created using a micropipette tip. Then, 1× PBS was used to wash and remove cell debris, and then cells were incubated with 0.3% FBS-supplemented DMEM medium to enable migration through the wounds. Images were acquired using an Axio Observer Z1 Inverted Epi-fluorescence microscope (Zeiss), equipped with an AxioCam HRm3 digital CCD camera, a Stage Controller XY STEP SMC 2009 scanning stage, and an Incubator XL multi S1 and Heating Unit XL S1 for live imaging incubation. Images were obtained under bright field illumination every 20 min for 6 h, using a 10× air objective and Zen Blue 2011 (Zeiss) software for image acquisition. Image analysis was performed with Fiji software, using an automated analysis macro to measure the occupied area by cells, and the results are presented as the wound covered area at the end of the experiment, relative to time = 0 h.

2.10. Noble Agar Invasion Assay

The procedure was performed as described previously, with minor modifications [17–19]. A 1% noble agar solution was heated until boiling, swirled to facilitate complete dissolution, and then taken off of the heat. When the temperature cooled to 50 °C, 5 μL spots were pipetted onto 96 well cell culture plates and allowed to cool for 20 min at RT under the hood. In total, $5 \times 10^3$ cells were then plated in the presence of 10% FBS cell culture media supplemented with 1 μg/mL Hoechst 33,258 (ThermoFisher Scientific, Carlsbad, CA, USA) and allowed to adhere for 1 h. Fluorescent images of the edges of each spot were taken every 20 min during 18 h on an Axio Observer Z1 (Zeiss) Fluorescence Microscope using a 10× magnification air objective, equipped with CCD AxioCam HRm3 digital Camera, and a XL multi S1 (D) incubation unit plus a XL S1 (D) temperature module to maintain cell culture conditions at 37 °C and 5% CO₂. Acquisition was controlled with Zen Blue 2011 (Zeiss) Software.

The number and position of cells was determined using image analysis software, ImageJ/Fiji “Trackmate” plug-in [20].

2.11. In Vivo Screen and Experimental Metastasis Model

NOD/SCID mice were originally purchased from Jackson Laboratories (Bar Harbor, ME, USA) and bred in the Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA)-CONICET-Partner Institute of the Max Planck Society animal facility under a pathogen-free environment. For all experiments, 7/8-week-old mice were used in accordance with protocols approved by the Institutional Board on Animal Research and Care
Committee (CICUAL, Experimental Protocol No. 63, 22.nov.2016), Facultad de Ciencias Exactas y Naturales (School of Exact and Natural Sciences), University of Buenos Aires.

For the in vivo screen, $1 \times 10^6$ cells containing the shRNA library were resuspended in 200 $\mu$L of sterile $1 \times$ PBS and injected in the lateral tail vein of male mice. At endpoint, mice were euthanized, and lungs and brains were resected for isolation of primary cultures. Approximately 100 mg of tissue were grossly chopped with a scalpel, and the resulting mixture was suspended in 500 $\mu$L of 0.075 mg/mL Collagenase Type IA (Sigma) and incubated at 37 $^\circ$C. After 30 min, dissolved material was centrifuged at 1000 rpm for 5 min and the supernatant was discarded. The pellet containing tumor cells was then resuspended in 2 mL of red blood cells lysis buffer (155 mM NH$_4$Cl, 10 mM KHCO$_3$, 0.1 mM EDTA; pH 7.3) and incubated at 4 $^\circ$C for 3 min. Five volumes of assay medium were then added, and the centrifugation step was repeated. The tumor cell sediment was then resuspended in 3 mL of assay medium, seeded in cell culture dishes, and incubated at 37 $^\circ$C and 5% CO$_2$.

For the experimental metastasis assay, $1 \times 10^6$ HERC1-silenced or control cells were resuspended in 200 $\mu$L of sterile $1 \times$ PBS and injected in the lateral tail vein of male mice. Sixty days post injection, lungs were harvested, fixed in buffered formalin, and stored in 70% ethanol until DNA extraction and metastatic load quantification following experimental procedures as described previously [21].

2.12. Tumorigenesis Model

For in vivo mouse tumor studies, $5 \times 10^5$ transduced cells were suspended in 100 $\mu$L of sterile $1 \times$ PBS and subcutaneously injected in the mammary fat pads of female mice. Tumors were measured every 3 days, and tumor volumes were calculated using the following formula: Vol (volume) = $\frac{1}{2}$ (width$^2$ * length). Area Under Curve (AUC) analysis was performed using measurements from mice that were alive at the end of the experiment.

2.13. In Silico Analysis

The KM-Plotter database contains proteomic data regarding the survival of 65 patients with breast cancer (Overall Survival (OS) data). The association between the HERC1 protein expression levels and OS was analyzed using an online KM-Plotter database [22] using the protein expression data and the survival information of patients with breast cancer downloaded from the GEO [23]. Cohorts of patients were split by auto-select best cutoff expression values. All subtypes of breast cancer samples were included in the analysis. The Kaplan–Meier survival plots with number at risk, hazard ratio (HR), 95% confidence intervals (CI), and log-rank $p$-values were obtained using the Kaplan–Meier plotter website (https://kmplot.com/analysis/index.php?p=service&cancer=breast_protein, accessed on 28 October 2020).

2.14. Statistical Analysis

Results are presented as box-and-whisker plots with median interquartile ranges plus minimum to maximum. n indicates the number of independent biological replicates. The one-way ANOVA with Dunnett’s multiple-comparison test as well as non-parametric Kruskal–Wallis and Dunn’s Tests were used to compare treatments to their corresponding control, and adjusted $p$-values are indicated. $p$-value differences of $<0.05$ (*), $<0.01$ (**), $<0.001$ (***) or $<0.0001$ (****) were considered statistically significant. GraphPad Prism statistical software (version 8.2.1, GraphPad Software, San Diego, CA, USA) was used for the analysis.

3. Results

3.1. Phenotypic Screening for Positive Regulators of Migration

We implemented a loss-of-function screen following an experimental protocol using a TNBC-derived cell line (MDA-MB-231), Boyden chambers, and mice to identify positive cell migration regulators within the UPS (Figure 1A). We generated stable cell lines infected
with an shRNA library directed against over 400 UPS genes (using around five shRNAs per gene) or an empty vector as a control. We then subjected these populations of cells to in vitro migration assays and amplified the non-migratory cells. We repeated this experiment several times to further enrich our population of interest, using the non-migratory cells from each migration experiment for the subsequent cycle of selection (Figure 1B). Once the proportion of non-migrating cells reached a plateau, we inoculated these poorly migratory cells in NOD/SCID mice through tail vein injection. After two months, we resected lungs and brains from injected mice, purified the human cells, and analyzed the relative abundance of the shRNAs compared to the cells prior to injection. Using this approach, we observed that four genes had decreased levels of shRNAs targeting their expression in the tissues-derived cell lines, compared to the initially injected cells, thus indicating that their expression may be needed for in vivo invasion (Figure 1C). Among the candidate genes, Appbp1, Usp26, and Fbxl20 had already been reported as positive regulators of metastasis [24–27], indicating that our strategy was successful. In contrast, the role of HERC1 in the control of tumor cell invasion has not been studied yet, and therefore we decided to further investigate its potential as a novel molecular target in breast cancer.

3.2. Proliferation Is Unaffected by HERC1 Silencing

Since alteration of proliferation rates might account partially for the selected phenotype, we measured doubling time of HERC1 silenced and control cell lines. To this end, we generated HERC1 knockdown (KD) cell lines with two different shRNAs (named shRNA #1 and #2) and used an empty vector-transduced cell line as a control (Figure 2A). Our results indicate that HERC1 KD does not affect proliferation in MDA-MB-231 cells (Figure 2B). We further validated these results using another breast cancer cell line (Figure S1).

Next, we analyzed whether HERC1 KD affects breast cancer cell clonogenicity. For that purpose, we plated cells at low confluence and analyzed the resulting colonies after two weeks. We did not observe significant differences in colony number or size between KD and control cell lines (Figure 2C).

Altogether, our results indicate that proliferation is unaffected by HERC1 expression knockdown in TNBC cell lines.

3.3. Validation of HERC1 as a Candidate Gene Regulating Migration

To validate HERC1 as a positive regulator of migration, we performed two independent cell migration assays.

Firstly, we subjected cells to Boyden chamber assay and observed a reduction in the number of migrating cells in HERC1 KD lines, compared to the control cell line (Figure 3A).

Secondly, we used wound healing assays. To this end, we scratched a confluent cell monolayer using a pipette-tip and analyzed cells movement across the gap. Our results show that HERC1 KD significantly decreased the migratory potential of cells relative to their control (Figure 3B). We observed similar results when another breast cancer cell line was used (Figure S1).

Overall, these experiments indicate that HERC1 silencing affects cell migration in vitro.

3.4. HERC1 Regulates Cell Invasion

Next, we assessed cell invasiveness using agar spot assay and analyzed the distance covered by the cells inside the agar spot. We observed a significant reduction in HERC1 KD cells displacement, compared to the control cell line (Figure 3C). In addition, we performed this experiment using another breast cancer cell line, obtaining similar results. These observations indicate that HERC1 KD-dependent alteration in migration also results in a significant reduction in breast cancer cell invasive potential.
Figure 1. shRNA-based selection of positive regulators of cell migration. (A) Overview of the selection procedure. The production and infection of an ubiquitylation-related lentiviral shRNA library are described in Methods. Two weeks after lentiviral infection and selection, MDA-MB-231 cells were seeded onto Boyden chamber inserts and allowed to migrate across the porous membrane at 37 °C for 24 h in order to select cells with a decreased migration phenotype. Migrating cells were removed and non-migrating cells were collected by trypsin treatment from the inserts upper compartment and cultivated for one week. Cells were then reseeded onto Boyden chamber culture inserts for a subsequent round of selection; this procedure was repeated until cells lost 75% of their initial migratory potential. This non-migratory population of cells was then inoculated through tail vein injection into NOD/SCID mice, and primary cultures were generated after two months from lung and brain tissues. shRNAs were retrieved by PCR from the in vitro and in vitro/vivo-selected cells, and then identified by Next Generation Sequencing (NGS). (B) Boyden chamber assay was used every other enrichment cycle to determine the relative percentage of migratory cells and monitor the selection process. (C) shRNAs abundance after the in vivo selection, relative to their abundance in the in vitro-selected non-migratory cells.
Figure 2. Proliferation is unaffected by HERC1 depletion. MDA-MB-231 cells were stably transduced with an empty vector (control) or two different shRNAs (#1 and #2) targeting HERC1. (A) Efficiencies of shRNA-mediated target gene knockdown were confirmed by RT-PCR (top, $n = 7$, one-way ANOVA, Dunnett’s multiple comparison test; shRNA #1 $p = 0.0014 (**)$ and shRNA #2 $p = 0.0365 (*)$). (B) An area-based microscopy method was used to determine cell growth over time. Cells were seeded onto wells and allowed to attach. At the indicated time points, cells were photographed, and the occupied area was calculated. The graph shows the occupied area relative to time = 0 h. Doubling times = control, 47.01 ± 0.2087; shRNA #1, 46.23 ± 0.3667; shRNA #2, 47.38 ± 1.023 ($n = 3$, Kruskal–Wallis, Dunn’s multiple comparison test; shRNA #1 $p > 0.9999$ and shRNA #2 $p = 0.4503$). (C) Cells were subjected to colony formation assay: (Top) representative images of the crystal violet-stained 100 mm dishes at the end of the experiment; (Bottom Left) number of colonies generated after 15 days ($n = 3$, Kruskal–Wallis, Dunn’s multiple comparison test; shRNA #1 $p > 0.9999$ and shRNA #2 $p = 0.4661$); and (Bottom Right) diameter of the resulting colonies ($n = 3$, Kruskal–Wallis, Dunn’s multiple comparison test; shRNA #1 $p = 0.1473$ and shRNA #2 $p > 0.9999$).

3.5. In Vivo Validation

To further characterize HERC1-dependent control of cell invasion in vivo, we performed two different experiments using immunocompromised mice. We first injected MDA-MB-231 control or HERC1-silenced cells subcutaneously in the mammary fat pad of female mice and monitored tumor growth every 2–3 days. Tumor growth curves analysis indicated that those generated from MDA-MB-231 HERC1-silenced cells were significantly less volumetric than the ones originated from control cells. Moreover, Kaplan–Meier analysis of tumor-free survival indicated that HERC1 silencing affected tumor development (Figure 4A).
Figure 3. Validation and characterization of HERC1 as a candidate migration and invasion regulatory gene. Cells migratory potential was evaluated by two different experiments. (A) Boyden chamber assay: number of migratory cells per Boyden chamber membrane ($n \geq 12$, one-way ANOVA, Dunnett’s multiple comparison test; shRNA #1 $p = 0.0180$ (*) and shRNA #2 $p = 0.0009$ (***)). (B) Wound healing assay: (Top Left) representative areas in a wound healing experiment at the indicated time points, scale bar = 100 µm; (Top Right) wound covered area (mm$^2$) at the indicated time points; (Bottom Left) wound edge closing speed ($n = 5$, one-way ANOVA, Dunnett’s multiple comparison test; shRNA #1 $p < 0.0001$ (****) and shRNA #2 $p = 0.0002$ (***)); and (Bottom Right) wound covered area (mm$^2$) at endpoint ($n = 5$, one-way ANOVA, Dunnett’s multiple comparison test; shRNA #1 $p < 0.0001$ (****) and shRNA #2 $p = 0.0024$ (*)). (C) Agar spot assay: cells were seeded in wells with drops of solidified agar and invaded along the bottom surface under the agar. Pictures were taken along the edge and the displacement is the extent of invasion under agar from the spot edge to cells final position: (Left) representative area showing cell invasion into an agar spot at the indicate time points, scale bar = 150 µm; and (Right) cells mean displacement at the end of the experiment ($n = 3$, Kruskal–Wallis, Dunn’s multiple comparison test; shRNA #1 $p = 0.0146$ (*) and shRNA #2 $p = 0.3594$).
Figure 4. In vivo and in silico analysis of HERC1 relevance in tumor biology and patients’ survival. (A) Downregulation of HERC1 attenuates tumorigenicity in vivo. Control or HERC1-silenced MDA-MB-231 cells were subcutaneously inoculated into the mammary fat pads of female NOD/SCID mice and tumor growth was monitored every 2–3 days: (Top Left) tumor volume was calculated at the indicated time points (results show mean value ± s.e.m.); (Bottom Left) Area Under Curve (AUC) was performed to analyze differences between treatments (n ≥ 4, Kruskal–Wallis, Dunn’s multiple comparison test; shRNA #1 p = 0.0171 (*) and shRNA #2 p = 0.0038 (**)); (Top Right) Kaplan–Meier curves for Tumor Free Survival (TFS) in mice injected with control or HERC1-silenced cells; and (Bottom Right) log-rank test (Mantel–Cox) analysis (HR, hazard ratio; CI, confidence interval) (n ≥ 4, log-rank (Mantel–Cox) test; shRNA #1 p = 0.0127 (*) and shRNA #2 p = 0.0011 (**)). (B) Silencing effects of HERC1 on experimental metastasis assays: NOD/SCID male mice were inoculated with MDA-MB-231 control or HERC1-silenced cells through tail vein injection and lungs were harvested after two months: (Left) Representative images of lungs at endpoint; metastatic foci are indicated with arrows. M⁺, ratio of lungs positive for metastatic growth versus the number of injected mice. (Right) Experimental metastasis (AU) was estimated by qPCR human DNA quantification, normalized to mouse DNA (n = 8, Kruskal–Wallis, Dunn’s multiple comparison test; shRNA #1 p = 0.0127 (*) and shRNA #2 p = 0.0011 (**)). (C) Kaplan–Meier curves for breast carcinoma patients’ Overall Survival (OS) according to HERC1 protein expression status in primary tumors: red solid line and black dashed line indicate cases with high and low expression of HERC1, respectively (n =65, Log-Rank (Mantel–Cox) test, p = 0.019 (*)).
We then inoculated control or HERC1-silenced MDA-MB-231 cells through tail vein injection and harvested the lungs two months later. As shown in Figure 4B, HERC1 depletion reduces metastatic load in vivo, as evaluated by human DNA quantification. Our results indicate that HERC1 silencing decreases cell engraftment and tumor growth, as well as colonization into the lungs.

3.6. In Silico Analysis for HERC1 Protein Expression

Finally, we conducted an in silico analysis to study the association between HERC1 protein expression levels in the primary tumors and breast cancer patient’s overall survival (OS), using an online KM-Plotter database. We built Kaplan–Meier plots by dividing the patients into two groups based on the expression of HERC1 protein and observed a significant separation between the survival curves, with a worse prognosis associated with higher expression levels (Figure 4C).

These findings indicate that HERC1 shows great potential as a new predictor of OS in breast cancer.

4. Discussion

Cell migration and invasion are critical steps in the metastatic dissemination of tumor cells, a process that constitutes the principal cause of death due to solid tumors [1]. In fact, it has been reported that the regulation of transcriptional pathways related to migration, rather than proliferation, are strongly associated with breast cancer patient’s survival [28], highlighting the importance of its modulation in the development of new treatments for the clinical management of this disease.

For that purpose, we performed a genetic screen and a functional assay that involved both in vitro and in vivo experiments, in order to find genes related to the UPS with novel functions as regulators of cell motility. Using this approach, we identified HERC1 as a putative positive regulator of migration in human breast cancer.

HERC1 is a HECT E3 ligase that is restricted to the cytoplasm and Golgi/vesicular-like membrane compartments [29]. Mutations of HERC1 gene or its deregulation have been associated with different pathologies, including neurological disorders [30–41] and cancer [42,43].

Our in vitro validation experiments showed that HERC1 depletion did not affect cell proliferation but directly inhibited cellular migration in Boyden chamber and wound healing assays, as well as invasion. In the course of our studies, Herc1 was reported as a regulator of migration, further supporting our findings [44].

In vivo studies using immunocompromised mice demonstrated that HERC1 silencing decreased tumor growth and colonization into the lungs in experimental metastasis assays. Finally, we investigated the prognostic value of HERC1 protein expression in patients with breast cancer using the Kaplan–Meier plotter database. Our study indicated that higher levels of HERC1 protein are significantly associated with decreased overall survival, compared to patients that express low levels of HERC1. In concordance with our results, it has been demonstrated that HERC1 protein shows increased expression in tumor cell lines [29] and tumor breast cancer patients’ samples [45], compared to their respective normal counterpart.

5. Conclusions

Altogether, our results indicate that HERC1 has great potential as a putative new target for the treatment of breast cancer and that its modulation could directly or indirectly regulate tumor cell motility and therefore patient’s outcome. Since HERC1 harbors catalytic activity, it would be attractive to further study whether its role in migration regulation is dependent on its E3 ligase activity. Lastly, our results highlight the importance of functional migration-based screens, as a complement to assays based on proliferation, for the discovery of putative new targets for the treatment of tumorigenesis.
**Supplementary Materials:** The following are available online at https://www.mdpi.com/2072-6694/13/6/1309/s1, Figure S1: HERC1 validation using MDAMB436 cells. Table S1: shRNAs sequences targeting Ubiquitin Proteasome System (UPS)-related genes.

**Author Contributions:** Conceptualization, F.A.R. and M.R.; design, F.A.R. and E.H.C.R.; methodology, F.A.R. and E.H.C.R.; validation, F.A.R. and E.H.C.R.; formal analysis, F.A.R. and E.H.C.R.; investigation, F.A.R., E.H.C.R. and J.H.E.S.; resources, M.U.J. and J.M.E.; writing—original draft preparation, F.A.R., J.H.E.S., E.H.C.R. and M.R.; writing—review and editing, F.A.R. and M.R.; visualization, F.A.R. and E.H.C.R.; supervision, M.R.; project administration, M.R.; and funding acquisition, J.M.E. and M.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by grants from the Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) PICT 2011-2783, PICT 2016-2620 and PICT 2018-03688 awarded to M.R.; J.E. was supported by NIH R01CA117907, NIH R01GM120109, NSF MCB-1817582 and NIH P30CA046934 grants; F.R. and J.E.S. are postdoctoral fellows of Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); and E.C.R. was recipient from a fellowship from Instituto Nacional del Cáncer (INC).

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Board on Animal Research and Care Committee (CICUAL, Experimental Protocol No. 63, 22.nov.2016), Facultad de Ciencias Exactas y Naturales (School of Exact and Natural Sciences), University of Buenos Aires.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available in this article (and Supplementary Materials).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Gupta, G.P.; Massagué, J. Cancer Metastasis: Building a Framework. Cell 2006, 127, 679–695. [CrossRef]

2. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646–674. [CrossRef]

3. Gallo, L.H.; Ko, J.; Donoghue, D.J. The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle 2017, 16, 634–648. [CrossRef] [PubMed]

4. Désaies, R.J. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014, 12, 94. [CrossRef]

5. Ciechanover, A. The ubiquitin proteolytic system: From a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 2005, 66, S7–S19. [CrossRef]

6. Paul, S. Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: Therapeutic approaches. BioEssays 2008, 30, 1172–1184. [CrossRef] [PubMed]

7. Petroski, M.D. The ubiquitin system, disease, and drug discovery. BMC Biochem. 2008, 9, S7. [CrossRef] [PubMed]

8. Popovic, D.; Vucic, D.; Dikic, I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 2014, 20, 1242–1253. [CrossRef]

9. Reinstein, E.; Ciechanover, A. Narrative review: Protein degradation and human diseases: The ubiquitin connection. Ann. Intern. Med. 2006, 145, 676–684. [CrossRef]

10. Hoeller, D.; Dikic, I. Targeting the ubiquitin system in cancer therapy. Nat. Cell Biol. 2009, 438, 438–444. [CrossRef]

11. Garrido-Castro, A.C.; Lin, N.U.; Polyak, K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019, 9, 176–198. [CrossRef] [PubMed]

12. Lee, K.-L.; Kuo, Y.-C.; Ho, Y.-S.; Huang, Y.-H. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. Cancers 2019, 11, 1334. [CrossRef] [PubMed]

13. Mehanna, J.; Haddad, F.G.; Eid, R.; Lambertini, M.; Kourie, H.R. Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape. Int. J. Women’s Health 2019, 11, 431–437. [CrossRef]

14. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 2012, 9, 676–686. [CrossRef]

15. Bahnsen, A.; Athanassiou, C.; Koebler, D.; Qian, L.; Shun, T.; Shields, D.; Yu, H.; Wang, H.; Goff, J.; Cheng, T.; et al. Automated measurement of cell motility and proliferation. BMC Cell Biol. 2005, 6, 19. [CrossRef] [PubMed]

16. Geissmann, Q. OpenCFU, a New Free and Open-Source Software to Count Cell Colonies and Other Circular Objects. PLoS ONE 2013, 8, e54072. [CrossRef]

17. Ahmed, M.; Basheer, H.A.; Ayuso, J.M.; Ahmet, D.; Mazzini, M.; Patel, R.; Shnyder, S.D.; Vinader, V.; Afarinkia, K. Agarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple Chemokines. Sci. Rep. 2017, 7, 1075. [CrossRef] [PubMed]

18. Salvany, L.; Müller, J.; Guccione, E.; Rorth, P. The core and conserved role of MAL is homeostatic regulation of actin levels. Genes Dev. 2014, 28, 1048–1053. [CrossRef]
19. Wiggins, H.; Rappoport, J. An agarose spot assay for chemotactic invasion. *Biotechniques* **2010**, *48*, 121–124. [CrossRef]

20. Tinevez, J.-Y.; Perry, N.; Schindelin, J.; Hoopes, G.M.; Reynolds, G.D.; Laplantine, E.; Bednarek, S.Y.; Shorte, S.L.; Eliezer, K.W. TrackMate: An open and extensible platform for single-particle tracking. *Methods* **2017**, *115*, 80–90. [CrossRef]

21. Llorens, M.C.; Rossi, F.A.; Garcia, I.A.; Cooke, M.; Abba, M.C.; Lopez-Haber, C.; Barrio-Real, L.; Vaglienti, M.V.; Rossi, M.; Bocco, J.L.; et al. PKCa Modulates Epithelial-to-Mesenchymal Transition and Invasiveness of Breast Cancer Cells Through ZEB1. *Front. Oncol.* **2019**, *9*, 1323. [CrossRef] [PubMed]

22. Gyöffy, B.; Lanzczky, A.; Ecklund, A.C.; Denkert, C.; Budeczies, J.; Li, Q.; Szallasi, Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. *Breast Cancer Res. Treat.* **2009**, *123*, 725–731. [CrossRef] [PubMed]

23. Tang, W.; Zhou, M.; Dorsey, T.H.; Prieto, D.A.; Wang, X.W.; Ruppin, E.; Veenstra, T.D.; Ambs, S. Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival. *Genome Med.* **2018**, *10*, 1–14. [CrossRef] [PubMed]

24. He, F.; Zhang, C.; Chen, X.; Luo, J.; Wu, Q. FBXL20 promotes cell proliferation and metastasis through activating Wnt/β-catenin signaling pathway in esophageal cancer. *Int. J. Clin. Exp. Med.* **2017**, *10*, 7796–7805.

25. Jin, Y.; Zhang, P.; Wang, Y.; Jin, B.; Zhou, J.; Zhang, J.; Pan, J. Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma. *Clin. Cancer Res.* **2017**, *24*, 3741–3754. [CrossRef] [PubMed]

26. Li, L.; Zhou, H.; Zhu, R.; Liu, Z. USP26 promotes esophageal squamous cell carcinoma metastasis through stabilizing Snail. *Cancer Lett.* **2019**, *448*, 52–60. [CrossRef] [PubMed]

27. Zhu, J.; Deng, S.; Duan, J.; Xie, X.; Xu, S.; Ran, M.; Dai, X.; Pu, Y.; Zhang, X. FBXL20 acts as an invasion inducer and mediates E-cadherin in colorectal adenocarcinoma. *Oncol. Lett.* **2014**, *7*, 2185–2191. [CrossRef]

28. Nair, N.U.; Das, A.; Rogkoti, V.-M.; Fokkelman, M.; Marcotte, R.; De Jong, C.G.; Koedoot, E.; Lee, J.S.; Meilijson, I.; Hannenhalli, S.; et al. Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival. *Sci. Rep.* **2019**, *9*, 10989. [CrossRef]

29. Rosa, J.L.; Casaroli-Marano, R.P.; Buckler, A.J.; Vilaro, S.; Barbacid, M. p619, a giant protein related to the chromosome condensation regulator RCC1, stimulates guanine nucleotide exchange on ARF1 and Rab proteins. *EMBO J.* **1996**, *15*, 4262–4273. [CrossRef]

30. Aggarwal, S.; Das Bhownik, A.; Ramprasad, V.L.; Murugan, S.; Dalal, A. A splice site mutation in HERC1 leads to syndromic intellectual disability with macrocephaly and facial dysmorphism: Further delineation of the phenotypic spectrum. *Am. J. Med. Genet. Part A* **2016**, *170*, 1868–1873. [CrossRef] [PubMed]

31. Bachiller, S.; Rocas-Ceballos, M.A.; Garcia-Dominguez, I.; Pérez-Villegas, E.M.; Martos-Carmona, D.; Pérez-Castro, M.Á.; Real, L.M.; Rosa, J.L.; Tabares, L.; Venero, J.L.; et al. HERC1 Ubiquitin Ligase Is Required for Normal Axonal Myelination in the Peripheral Nervous System. *Mol. Neurobiol.* **2018**, *55*, 8856–8868. [CrossRef]

32. Bachiller, S.; Rybkina, T.; Porras-Garcia, E.; Perez-Villegas, E.; Tabares, L.; Armengol, J.A.; Carrion, A.M.; Ruiz, R. The HERC1 E3 Ubiquitin Ligase is essential for normal development and for neurotransmission at the mouse neuromuscular junction. *Cell. Mol. Life Sci.* **2015**, *72*, 2961–2971. [CrossRef]

33. Hashimoto, R.; Nakazawa, T.; Tsurusaki, Y.; Yasuda, Y.; Nagayasu, K.; Matsumura, K.; Kawashima, H.; Yamamori, H.; Fujimoto, M.; Ohi, K.; et al. Whole-exome sequencing and neurite outgrowth analysis in autism spectrum disorder. *J. Hum. Genet.* **2016**, *61*, 199–206. [CrossRef] [PubMed]

34. Kannan, M.; Bayam, E.; Wagner, C.; Rinaldi, B.; Kretz, P.F.; Tilly, P.; Roos, M.; McGilliwie, L.; Bär, S.; Minocha, S.; et al. WD40-repeat 47, a microtubule-associated protein, is essential for brain development and autophagy. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E9308–E9317. [CrossRef] [PubMed]

35. Lei, J.; Xu, H.; Liang, H.; Su, L.; Zhang, J.; Huang, X.; Song, Z.; Le, W.; Deng, H. Gene expression changes in peripheral blood from Chinese Han patients with Tourette Syndrome. *Am. J. Med. Genet. Part B Neurogeneogr. Genet.* **2012**, *159B*, 977–980. [CrossRef] [PubMed]

36. Nguyen, L.S.; Schneider, T.; Rio, M.; Moutton, S.; Siquier-Pernet, K.; Verny, F.; Boddart, E.; Desguerre, I.; Munich, A.; Rosa, J.L.; et al. A nonsense variant in HERC1 is associated with intellectual disability, megalencephaly, and facial dysmorphism. *Eur. J. Hum. Genet.* **2016**, *24*, 455–458. [CrossRef] [PubMed]

37. Mashimo, T.; Hadjebi, O.; Amair-Pinedo, F.; Tsurumi, T.; Lang, A.; Serikawa, T.; Sotelo, C.; Guénat, J.-L.; Rosa, J.L. Progressive Purkinje Cell Degeneration in tambaleante Mutant Mice Is a Consequence of a Missense Mutation in HERC1 E3 Ubiquitin Ligase. *PLoS Genet.* **2009**, *5*, e1000784. [CrossRef] [PubMed]

38. Pérez-Villegas, E.M.; Negrete-Diaz, J.V.; Porras-García, M.E.; Ruiz, R.; Carrion, A.M.; Rodriguez-Moreno, A.; Armengol, J.A.; De Mújica, J.; Angel, A.B. Mutation of the HERC1 Ubiquitin Ligase Impairs Associative Learning in the Lateral Amygdala. *Mol. Neurobiol.* **2017**, *55*, 1157–1168. [CrossRef] [PubMed]

39. Puffenberger, E.G.; Jinks, R.N.; Wang, H.; Xin, B.; Fiorentini, C.; Sherman, E.A.; Degrazio, D.; Shaw, C.; Sougnez, C.; Cibulskis, K.; et al. A homozygous missense mutation in HERC2 associated with global developmental delay and autism spectrum disorder. *Hum. Mutat.* **2012**, *33*, 1639–1646. [CrossRef] [PubMed]

40. Rosner, M.; Hannerd, M.; Siegel, N.; Vahl, A.; Hengstschläger, M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. *Mutat. Res. Rev. Mutat. Res.* **2008**, *658*, 234–246. [CrossRef] [PubMed]
41. Utine, G.E.; Taşkiran, E.Z.; Koşukcu, C.; Karaosmanoğlu, B.; Güleray, N.; Doğan, Ö.A.; Kiper, P.; Özlem, Ş.; Boduroğlu, K.; Alıkasifoğlu, M. HERC1 mutations in idiopathic intellectual disability. *Eur. J. Med. Genet.* 2017, 60, 279–283. [CrossRef] [PubMed]

42. Diouf, B.; Cheng, Q.; Krynetskaia, N.F.; Yang, W.; Cheok, M.; Pei, D.; Fan, Y.; Cheng, C.; Krynetskiy, E.Y.; Geng, H.; et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. *Nat. Med.* 2011, 17, 1298–1303. [CrossRef] [PubMed]

43. Holloway, A.; Simmonds, M.; Azad, A.; Fox, J.L.; Storey, A. Resistance to UV-induced apoptosis by β-HPV5 E6 involves targeting of activated BAK for proteolysis by recruitment of the HERC1 ubiquitin ligase. *Int. J. Cancer* 2014, 136, 2831–2843. [CrossRef]

44. Pedrazza, L.; Schneider, T.; Bartrons, R.; Ventura, F.; Rosa, J.L. The ubiquitin ligase HERC1 regulates cell migration via RAF-dependent regulation of MKK3/p38 signaling. *Sci. Rep.* 2020, 10, 1–14. [CrossRef] [PubMed]

45. Confalonieri, S.; Quarto, M.; Goisis, G.; Nuciforo, P.; Donzelli, M.; Jodice, G.; Pelosi, G.; Viale, G.; Pece, S.; Di Fiore, P.P. Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. *Oncogene* 2009, 28, 2959–2968. [CrossRef] [PubMed]